<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686114</url>
  </required_header>
  <id_info>
    <org_study_id>Shixiu - 1</org_study_id>
    <nct_id>NCT00686114</nct_id>
  </id_info>
  <brief_title>Concurrent Chemoradiotherapy Containing Paclitaxel&amp;Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer</brief_title>
  <official_title>Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is multi-center randomized phase III one to evaluate the difference in
      local-control and survival rate between patients receiving concurrent chemoradiotherapy
      combined Tarceva or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the esophageal carcinoma in II~III stage, routine dosage of Paclitaxel and platinum
      medicine chemotherapy concurrently radical radiotherapy is worthy to be studied. On this
      base, we advanced approach the enlarged field radiotherapy and the intervention of Tarceva.
      And we approach the therapeutic effect for this method theoretically, which may give a
      further reasonable guidance for the clinical therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>five years after enrollment</time_frame>
    <description>failure: death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>five years after enrollment</time_frame>
    <description>Failure: occurrence of local or regional progression, distant metastases, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local-regional control rate</measure>
    <time_frame>three years after enrollment</time_frame>
    <description>Failure: occurrence of local or regional progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>five years after enrollment</time_frame>
    <description>assessed by RTOG Acute Radiation Morbidity Scoring Criteria and RTOG/EORTC Late Radiation Morbidity Scoring Schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>five years after enrollment</time_frame>
    <description>assessed by the Functional Assessment of Cancer Therapy-Esophageal (FACT-E)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enlarged field + Paclitaxel + Cisplatin + Tarceva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enlarged field + Paclitaxel + Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional field + Paclitaxel + Cisplatin + Tarceva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional field + Paclitaxel + Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>135mg/m2, day 1 and day 29 of the radiotherapy.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva</intervention_name>
    <description>150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Erlotinib Hydrochloride Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Enlarged field radiotherapy</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Conventional field radiotherapy</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be confirmed Esophageal Carcinoma pathologically

          2. (EUS)I～IVa, without contraindication for radical radiotherapy

          3. Subjects haven't been given neither radiotherapy nor chemotherapy before

          4. Age 18-70,behavioral status evaluation ECOG scores 0—2 and anticipated survival more
             than 6 months

          5. In 7 days after being selected, subjects should follow the status: WBC ≥ 4.0 x 10^9/L;
             ANC ≥ 1.5x 10^9/L; PLT ≥ 100 x 10^9/L; Hb ≥ 90 g/L; serum Cr ≤ ULN; serum bilirubin ≤
             1.5 ULN; ALT/AST ≤ 1.5 ULN

          6. Subjects should sign for the informed consent

          7. Subjects should perform good compliance

          8. Male and female subjects who have the ability of fertility should take contraception
             during the whole course and also 3 months after last dosage.In 7 days before the
             inclusion, urine pregnancy tests of subjects should be negative.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy or targeted therapy

          2. Complete obstruction of the esophagus, or patients who have the potential to develop
             perforation

          3. Patients with a history of malignancy (except that skin carcinomas or in situ breast
             cancer, oral cancer and cervical cancer with expected survival ≥2 years

          4. Patients who multiple foci esophagus

          5. Patients who are/were given any other medicine tests currently/in last 4 weeks

          6. Experienced hypersensitiveness with similar medicine or other kinds of bio-medicines

          7. Women in status of pregnancy

          8. Patients who have complications exist as following:

        (1)Uncontrolled angina and heart failure, have a history of hospitalization in 3 months;
        (2)A history of myocardial infarction in the past 6 months; (3)There is a need for
        antibiotic treatment of acute bacterial or fungal infection; (4)Chronic obstructive
        pulmonary disease, or other lung disease requiring hospitalization; (5)Drug addiction,
        alcoholism and AIDS disease or long-term virus carriers; (6)Uncontrollable seizures, or
        loss of insight because of mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shixiu Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st affliated hospital of Wen Zhou Medical college</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shixiu Wu, MD</last_name>
    <phone>86-0577-8806-9372</phone>
    <email>wushixiu@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>1st affliated hospital of Wen Zhou Medical college</name>
      <address>
        <city>Wen Zhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shixiu Wu, M.D.</last_name>
      <phone>+86057788069372</phone>
      <email>wushixiu@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xuebang Zhang, M.D.</last_name>
      <email>baxuza@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shixiu Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>April 28, 2014</last_update_submitted>
  <last_update_submitted_qc>April 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Wu Shixiu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>radiosensitivity</keyword>
  <keyword>EGFR inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

